Small-Molecule Targeted Therapies Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Targeted Protein Degraders DMPK and Bioanalytical Services

Targeted protein degraders are not conventional inhibitors. PROTACs such as ARV-110 / bavdegalutamide and DT2216 combine a target-binding warhead, linker, and E3-ligase ligand into one high-complexity molecule.

Creative Proteomics develops LC-MS/MS and DMPK workflows that separate intact degrader exposure, CYP3A4 metabolism, linker stability, linker cleavage, fragment-level MetID, and microsome / hepatocyte study design.

Browse Targeted Degrader Index Request Custom PROTAC Method Support

Intact Degrader SignalQuantify parent PROTAC exposure while preserving architecture-level interpretation.

Linker LiabilityEvaluate linker stability, cleavage products, and parent-to-fragment relationships.

Fragment-Level MetIDMap CYP3A4 and Phase I products across warhead, linker, and E3-ligand regions.

Targeted Degrader Study Logic INTACT → LINKER → FRAGMENT

🧩

Bifunctional ArchitectureWarhead, linker, and E3-ligand regions require structure-aware interpretation.

🔗

Linker StabilityCleavage can generate warhead-related, linker-derived, or E3-ligand-related fragments.

⚙

CYP3A4 MetabolismPhase I products may occur across different structural regions of the degrader.

🧪

PROTAC Bioanalysis OutputLC-MS/MS and MetID workflows connect intact exposure with degradation-relevant liability.

Architecture-aware degrader bioanalysis.We connect intact degrader quantification, linker stability, linker cleavage MetID, CYP3A4 metabolism, microsome / hepatocyte workflows, and custom degrader panel development.

Targeted Degrader Drug Index

Find the Targeted Protein Degrader Behind the Study

Route each degrader by molecular architecture: intact PROTAC quantification, CYP3A4-mediated MetID, linker stability assessment, linker cleavage tracking, microsome / hepatocyte metabolism, or custom degrader panel development.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only degraders matching all selected values.

2 entries · Page 1 of 1

Analytical Pain Points

What Drives Assay Failure in Targeted Protein Degrader Studies?

PROTAC assays can fail when bifunctional degraders are treated like ordinary inhibitors. Intact parent signal, linker integrity, fragment-level biotransformation, high-complexity extraction, and CYP3A4 Phase I metabolism must be interpreted together.

Intact exposure does not prove linker stability

A degrader may be measurable as parent while undergoing linker cleavage or region-specific transformation. Parent-only LC-MS/MS can miss structural liability.

Our responsePair intact degrader quantification with linker stability checks, fragment-aware MetID, and sample preparation that preserves parent-to-fragment interpretation.

Stability & Degradation →

Linker cleavage creates multiple analytical targets

For ARV-110 / bavdegalutamide, linker cleavage may generate products with different retention, ionization, and MRM behavior from the intact degrader.

Our responseDefine parent, linker-derived, warhead-related, and E3-ligand-related analytical targets before method development.

MetID →

CYP3A4 metabolism must be region-aware

CYP-linked products in PROTACs may arise across the warhead, linker, or E3-ligand region instead of a single small-molecule core.

Our responseConnect microsome / hepatocyte CYP3A4 studies with structural-region-aware Phase I MetID.

Biotransformation →

High-complexity molecules need method tuning

PROTACs can show recovery, adsorption, carryover, solubility, and matrix-effect challenges due to size and physicochemical complexity.

Our responseOptimize extraction, chromatographic selectivity, internal standard planning, calibration, and carryover control for high-complexity degrader analytes.

Method Development →

Degrader panels require intact and fragment compatibility

Panels may need to monitor intact degraders, CYP metabolites, and cleavage-related fragments with very different analytical behavior.

Our responseDevelop custom degrader panels with analyte-specific extraction, structural-region-aware transitions, and MetID-compatible reporting.

Custom Panels →

Focused Service Paths

Four Practical Routes for Targeted Protein Degrader Studies

Instead of treating PROTACs as ordinary targeted therapy molecules, choose the route based on intact degrader exposure, CYP3A4 metabolism, linker stability, cleavage products, fragment-level interpretation, or custom panel development.

Intact Targeted Degrader Quantification

For ARV-110 / bavdegalutamide, DT2216, or related PROTAC concentration data in plasma, serum, tissue, cell lysate, or other matrices.

Parent-degrader exposure studies
Intact molecule LC-MS/MS
High-complexity analyte method setup
Matrix-specific quantification

LC-MS/MS Drug Quantification →

CYP3A4 Metabolism and Phase I MetID

For workflows where CYP3A4 metabolism or Phase I metabolite formation defines the targeted degrader readout.

ARV-110 CYP3A4 metabolism
DT2216 Phase I MetID
Microsome / hepatocyte analysis
Structure-region-aware metabolite mapping

Metabolite Identification →

Linker Stability and Cleavage Workflows

For studies where linker integrity, cleavage products, or parent-to-fragment interpretation determines the analytical strategy.

ARV-110 linker stability assessment
Linker cleavage product tracking
Warhead-linker fragment analysis
E3-ligand-related fragment review

Stability & Degradation →

Custom PROTAC and Degrader Panels

For multiple degraders, intact parent / fragment comparison, structural liability screening, or multi-analyte LC-MS/MS method development.

PROTAC comparison panels
Parent-plus-fragment workflows
Degrader stability screening
Structural-region-aware reporting

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Targeted Protein Degrader?

If you are working with a PROTAC, bifunctional degrader, linker-modified analog, CYP3A4 metabolism question, linker stability workflow, cleavage product mapping requirement, Phase I MetID objective, or multi-analyte degrader panel, a parent-only LC-MS/MS method may not be enough.

Share your target degrader, matrix, concentration range, degrader architecture, linker stability concern, CYP3A4 requirement, fragment-level MetID objective, microsome / hepatocyte model needs, and panel requirements.

Target degrader and matrix

Expected concentration range

Degrader architecture

Linker stability concern

CYP3A4 / MetID objective

Panel development needs

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →